Carna Biosciences (TSE:4572) Total Equity: 円309.2 Mil (As of Dec. 2025)


TSE:4572 Carna Biosciences Inc TSE:4572
24 GF Score
Price 円337.00
GF Value 円174.75
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Carna Biosciences Total Equity?

Carna Biosciences TSE:4572 -0.59% 24 Total Equity is 円309.2 Mil as of Dec. 2025. GuruFocus rates TSE:4572 with a GF Score™ of 24/100 and a GF Value™ of 円174.75 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Carna Biosciences's total equity for the quarter that ended in Dec. 2025 was 円309.2 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Carna Biosciences Total Equity Historical Data

* Premium members only.

The historical data trend for Carna Biosciences's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Carna Biosciences Total Equity Chart

Carna Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4,315.57 3,641.85 3,877.54 2,475.35 309.22

Carna Biosciences Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,475.35 1,955.99 1,391.12 309.22 -163.55
TSE:4572
24GF Score
Carna Biosciences Inc TSE:4572
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Carna Biosciences Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Carna Biosciences's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=1229.648-920.43
=309.2

Carna Biosciences's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=1229.648-920.43
=309.2

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of 円309.2 Mil mean?
Carna Biosciences (TSE:4572) has a Total Equity of 円309.2 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Carna Biosciences and its competitors.
Is Carna Biosciences' Total Equity too high?
Carna Biosciences' current Total Equity is 円309.2 Mil. Overall, Carna Biosciences has a GF Score™ of 24/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Carna Biosciences' Total Equity compare to VRTX and REGN?
Carna Biosciences' Total Equity of 円309.2 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Carna Biosciences and its competitors. Carna Biosciences's current Total Equity is 円309.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carna Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Carna Biosciences (TSE:4572) is currently considered Significantly Overvalued. The stock's GF Value™ is 円174.75, compared to a current price of 円337.00 — trading 92.8% above its estimated fair value. The current Total Equity is 円309.2 Mil. Carna Biosciences' overall GF Score™ is 24/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Carna Biosciences (TSE:4572), the current Total Equity is 円309.2 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Carna Biosciences (TSE:4572) Overvalued in 2026?

Based on GuruFocus' analysis, Carna Biosciences stock appears to be overvalued. The current stock price of 円337.00 is trading 92.8% above its estimated GF Value™ of 円174.75. GuruFocus considers Carna Biosciences to be Significantly Overvalued.

Key valuation signals for TSE:4572:

  • Total Equity: 円309.2 Mil
  • GF Value™: 円174.75 vs. price of 円337.00 (92.8% above fair value)
  • GF Score™: 24/100 with 6 warning signs

No single metric tells the full story. See the TSE:4572 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Carna Biosciences Business Description

Address BMA 3F 1-5-5 Minatojima-Minamimachi, Kobe, JPN, 650-0047
Carna Biosciences Inc is a Japanese company engaged in drug discovery support business and drug discovery and development business. The company identifies and develops medicines for the treatment of cancer and inflammatory diseases using own kinase drug discovery platform, QuickScout.
24GF Score

Get the complete analysis for TSE:4572

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円337.00
Price
円174.75
GF Value